English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

TO THE EDITOR—The recently published updated Infectious Diseases Society of America guideline on the management of adults with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) recommend that patients with HAP/VAP due to “carbapenem-resistant pathogens” susceptible only to polymyxins should receive, in addition to colistin by inhalation, systemic monotherapy with either polymyxin B or colistin [1]. This recommendation ignores the molecular heterogeneity of resistance mechanisms in these organisms and conflicts with accumulating data supporting the use of combination therapy for bacteremic infections due to some carbapenem-resistant Enterobacteriaceae (CRE), particularly those due to Klebsiella pneumoniae [2–4]. These retrospective studies provide evidence that, despite the presence of phenotypic carbapenem resistance, the addition of a carbapenem to a polymyxin to which the organism is susceptible is associated with improved outcomes in the treatment of infection due to carbapenemase-positive organisms. This has best been demonstrated with bacteremic infections due to carbapenemase-producing K. pneumoniae (KPC) that, have relatively low minimum inhibitory concentrations (MICs) (ie, ≤8 μg/mL) [5,6]. Although the relevant studies deal with bacteremic infections, there is no reason to presume that the same principles do not apply to the treatment of HAP/VAP. The predictability of response is, however, complicated by the fact that CRE oftenexpressmore thanonemechanismof resistance. For example, KPC-producing K. pneumoniae may possess altered porin expression and function, the presence of which is an independent risk factor for poor outcomes in KPC-infected patients treated with colistin and doripenem in combination [6]. Furthermore, the specific

clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)

Treatment of Hospital or Ventilator-Associated Pneumonia Due to Carbapenem-Resistant Enterobacteriaceae: Leveraging Molecular Resistance Testing and Combination Therapy to Improve Outcomes